Stay current with the latest press releases from within the industry.
Release issued 25th February 2003
Probiodrug AG announced today that the company has concluded its first in man dosing study of P93/01, its lead candidate to be developed for the treatment of type 2 diabetes. P93/01 is one of a number of proprietary DP IV- inhibitor molecules which showed promising safety and efficacy in preclinical studies.
Probiodrug AG is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of diabetes, obesity and other serious medical conditions based on its detailed understanding of the actions of Dipeptidyl Peptidase IV and related enzymes.
If you want to find out more about the company visit Probiodrug profile.
(6th July 2004) Probiodrug awarded a €1.9mio BioChancePlus grant
(18th June 2004) Prosidion and Probiodrug conclude metabolic deal
(16th December 2003) Probiodrug hosts Scientific Advisory Board December 12th & 13th
Clients in focus...